Granules India Shares Rise After USFDA EIR Grant and VAI Classification for Its Arm

Business Standard reports that Granules India’s arm received a USFDA Electronic Information Record (EIR). The approval also includes a VAI (Verified Access) classification. The regulatory milestone is expected to boost the company’s market confidence. Investors responded positively, driving a gain in Granules India’s share price. The EIR signifies compliance with U.S. pharmaceutical standards. The VAI classification may facilitate future product launches in the United States. The company plans to leverage the approval to expand its export portfolio. Analysts will watch how the development influences the firm’s growth trajectory.